Entrada Therapeutics reports clinical-stage biopharmaceutical developments tied to its intracellular genetic-medicine platform and Endosomal Escape Vehicle therapeutics. Company updates center on RNA-based and oligonucleotide programs for neuromuscular and inherited retinal diseases, including Duchenne muscular dystrophy programs for exon 44, 45, 50 and 51 skipping-amenable patients.
Recurring news includes clinical data and study progress for ELEVATE programs, updates on ENTR-601-44 and other DMD candidates, the partnered VX-670 program for myotonic dystrophy type 1, and pipeline expansion into ocular disease such as Usher syndrome. Financial results, cash runway commentary, investor conference participation and Nasdaq inducement equity grants also appear in company communications.
Entrada Therapeutics, Inc. (Nasdaq: TRDA) announced the closing of its initial public offering, successfully selling 9,075,000 shares at $20.00 each, raising approximately $181.5 million. All shares were offered by Entrada. The offering commenced trading on October 29, 2021. Underwriters also hold an option for an additional 1,361,250 shares within 30 days. Goldman Sachs, Cowen, and Evercore acted as joint book-running managers for this offering. The company focuses on innovative Endosomal Escape Vehicle (EEV™) therapeutics targeting previously inaccessible intracellular diseases.
Entrada Therapeutics (Nasdaq: TRDA) has priced its upsized initial public offering (IPO) of 9,075,000 shares at $20.00 per share, aiming for gross proceeds of approximately $181.5 million. This marks a significant step for the biotechnology firm focused on Endosomal Escape Vehicle (EEV™) therapeutics. Trading is set to commence on October 29, 2021, with the offering expected to close on November 2, 2021. The underwriters hold an option for an additional 1,361,250 shares as part of the IPO.